Monitor for additional insider selling or a change in trend; while this level of selling is not yet material enough to signal distress, continued outflows could indicate waning confidence among insiders.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $15.20entry
- T+1 · 9mo ago −2.24%α −0.92% · $14.86
- T+5 · 8mo ago +18.82%α +21.05% · $18.06
- T+20 · 8mo ago +23.95%α +27.74% · $18.84
- T+60 · 6mo ago +22.57%α +11.27% · $18.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A director at Dyne Therapeutics sold $2.53 million worth of shares in a single open-market transaction, representing a notable insider divestment. This sale accounts for approximately 0.08% of the company's $3.0B market cap and is consistent with recent insider selling activity totaling $2.6M over the past 30 days.
Key Financial Metrics
Key Facts
- Director Kersten Dirk sold 129,672 shares at $19.5151 per share for a total of $2,530,562.
- The transaction was an open-market sale (Form 4 code 'S').
- This sale represents approximately 0.08% of Dyne Therapeutics' $3.0B market capitalization.
- It is part of a broader pattern of insider selling, with four sales totaling $2.6M in the past 30 days.
Financial Impact
$2.53 million in insider sales over 7 days, $2.6M over 30 days
Risk Factors
- Ongoing insider selling may erode investor confidence if volume increases.
- Lack of offsetting insider buying reduces potential bullish signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (1 trades, 7d window) | cluster-DYN-1773434171885 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers